A higher proportion of patients with non-infectious uveitis experienced a reduction of their vitreous haze scores to 0 at 5 months after receiving a 440 µg dose of intravitreal sirolimus compared with ...

MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced ...

JERSEY CITY, N.J., Jul 09, 2012 -- Lux Biosciences, Inc. today announced the completion of patient enrollment in its Phase 3 clinical study of Luveniq(TM) (oral voclosporin) for the treatment of ...

AbbVie announced that the Food and Drug Administration (FDA) has approved Humira (adalimumab) for the treatment of non-infectious intermediate, posterior, and panuveitis. This approval marks the first ...

Ophthalmologist_TS_78024029 An injectable fluocinolone acetonide long-acting implant may be able to effectively control intraocular inflammation, as well as improve visual acuity, in patients with a ...

SAN FRANCISCO and SUZHOU, China, Dec. 22, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...

YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily, ...

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, ...

The display and use of drug information on this site is subject to express terms of use. By continuing to view the drug information, you agree to abide by such terms ...